At first glance, it might seem that small molecule discovery has reached a plateau. In reality, the truth couldn’t be more different. With small molecules making up over 60% of new drug approvals in 2021, it’s clear that the appetite for progression and potential for innovation is huge. The renaissance of small molecule drug discovery means one thing for certain: the race to explore uncharted biologically active chemical space is on.
Promising as the future looks, the process of discovery has multiple challenges that have an impact on time, cost and risk to any biotech professional working towards a therapeutic breakthrough.
During this one-hour webinar with Dotmatics’ Director of product marketing Haydn Boehm, we explore the current landscape and how things sit with small and large molecule research. Haydn also outlines the friction points scientists may encounter in the small molecule drug discovery process.
By watching this webinar, you will learn:
- Why research collaboration is vitally important for all scientists working in this field
- How to get the most out of data from multiple sources, by efficiently merging and managing all available data, wherever it comes from
- To optimise your workflow in accordance with your specific needs, ultimately improving cycle times, reducing costs and finding better candidates as quickly as possible
Speaker: Haydn Boehm
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists’ favorite applications drive efficiency and accelerate innovation. More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. The company’s principal office is in Boston, US, with 14 offices and R&D teams located around the world.
